SCRI

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW BriaCell Therapeutics, Corp./BC-IMT-04/Orr/5/8/2026/Continuing Review 1 of 2 MEETING MINUTES Meeting Date: Friday, May 8, 2026 Time: 1:00 pm Central Time Location: Zoom Teleconference Institution: Sarah Cannon Research Institute at Mary Crowley, Dallas, TX Principal Investigator: Douglas Orr, MD Protocol: BriaCell Therapeutics, Corp., BC-IMT-04 NCT Number: NCT06072612 Meeting Type: Continuing Review of Protocol and Site Title: Randomized, open-label study of the BRIA-IMT regimen and check point inhibitor vs physician's choice in advanced metastatic breast cancer (BRIA- ABC). 1. Call to order: The Meeting was called to order at 1:02 pm Central Time. 2. Introductions and orientation: Introductions were made and the Chair oriented members to the meeting procedures. 3. Declaration of quorum: Four voting members were present, including two local members unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present. 4. Conflict of Interest: The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported. 5. Public posting: An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review. 6. Approval of previous meeting minutes: Minutes Approved - YES: 4 NO: 0 ABSTAIN: 0 7. Review of proposed research: The Chair provided an overview of the protocol and status of the study. The Chair noted changes since the last review. 8. Determination for biosafety level and period of IBC oversight: The Committee previously determined that BSL-2 containment facilities and practices are required for SV- BR-1-GM, since it consists of human cells modified using a plasmid. The Committee reaffirmed this determination. The Committee previously determined that IBC oversight will continue for 3 months after the last subject's last dose of SV-BR-1-GM locally, provided that all biosafety criteria for study closure are also met. The Committee reaffirmed this determination. 9. Vote on the Protocol: The Committee voted for the following determination on the Protocol: X APPROVED CONDITIONALLY APPROVED TABLED DISAPPROVED DETERMINATION VOTE - YES: 4 NO: 0 ABSTAIN: 0

• Meeting Date: Friday, May 8, 2026